Organization Profile

You just read:

EPIGENE THERAPEUTICS INC. announces presentations on NEO2734, an oral dual inhibitor of both BET and CBP-P300, at the ASH 2018 Congress

News provided by

Epigene Therapeutics Inc.

Dec 03, 2018, 09:33 ET